THE EFFECTS OF LONG-ACTING METHYLPHENIDATE FORMULATIONS AND ATOMOXETINE ON CARDIAC FUNCTIONS IN CHILDREN WITH ATTENTION DEFICIT AND HYPERACTIVITY

Basit Öğe Kaydı
dc.contributor.authorMıhçıoğlu, Ajda Mutlu
dc.contributor.authorKara, Tayfun
dc.date.accessioned2026-01-24T12:00:52Z
dc.date.available2026-01-24T12:00:52Z
dc.date.issued2023
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractObjective: Methylphenidate (MPH) and atomoxetine (ATX) are most commonly prescribed for the treatment of attention deficit hyperactivity disorder (ADHD). In the literature, there are studies performed to evaluate each of these drugs, but there is no study comparing these three medications together. Therefore, we aimed to evaluate the cardiac effects of these medications. Methods: Forty-six children with ADHD using osmotic-release oral system MPH (OROS-MPH), 46 using extended-release MPH (ER-MPH), and 46 using ATX for at least six months were included in the patient groups. Forty-six children with normal cardiac findings were enrolled as the control group. All participants were evaluated using a sociodemographic information form, 12-channel electrocardiography (ECG), transthoracic 2D, Doppler and tissue Doppler echocardiography. Results: Statistically significant differences were observed in terms of A wave velocity, E/A and E’ septal values between the groups (p=0.002, p<0.001, p=0.002, respectively). Children using ATX had higher A wave velocities than the OROS-MPH users and controls (p<0.001 and p=0.007, respectively) and lower E/A values than the OROS-MPH users and controls (p<0.001 for both). Children using ER-MPH and ATX had lower E’ septal values compared to the control group (p<0.001 and p=0.002, respectively). Conclusion: Atomoxetine treatment showed impairment in some of the myocardial relaxation parameters more than long acting-MPH medications. In conclusion, although the drugs used in the treatment of ADHD are cardiac safe in general and do not cause clinical findings of heart failure, patients should be evaluated for cardiac involvement. Further studies are needed to support the findings in our study
dc.identifier.doi10.53446/actamednicomedia.1215509
dc.identifier.endpage106
dc.identifier.issn2717-8994
dc.identifier.issue1
dc.identifier.startpage98
dc.identifier.trdizinid1161598
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1161598
dc.identifier.urihttps://doi.org/10.53446/actamednicomedia.1215509
dc.identifier.urihttps://hdl.handle.net/20.500.12868/3789
dc.identifier.volume6
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.relation.ispartofActa Medica Nicomedia
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_TR-Dizin_20260121
dc.subjectChildren
dc.subjectattention deficit and hyperactivity disorder
dc.subjectMethylphenidate
dc.subjectAtomoxetine
dc.subjecttissue Doppler imaging
dc.titleTHE EFFECTS OF LONG-ACTING METHYLPHENIDATE FORMULATIONS AND ATOMOXETINE ON CARDIAC FUNCTIONS IN CHILDREN WITH ATTENTION DEFICIT AND HYPERACTIVITY
dc.typeArticle

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu